Vivoryon Therapeutics NV (FRA:05Y) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vivoryon Therapeutics NV's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Vivoryon Therapeutics NV's long-term debt to total assets ratio declined from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that Vivoryon Therapeutics NV is progressively becoming less dependent on debt to grow their business.

Vivoryon Therapeutics NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Vivoryon Therapeutics NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivoryon Therapeutics NV LT-Debt-to-Total-Asset Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Vivoryon Therapeutics NV LT-Debt-to-Total-Asset Calculation

Vivoryon Therapeutics NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	30.829
	=	0.00

Vivoryon Therapeutics NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	30.829
	=	0.00

Vivoryon Therapeutics NV (FRA:05Y) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vivoryon Therapeutics NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

VVY:Netherlands

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines